Japanese encephalitis vaccine solution for injection 1ml vials
Any of several vaccines against Japanese encephalitis
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Japanese encephalitis vaccine
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 22 · Randomised trials: 13 · 1970–2026
Showing the 50 most relevant studies, sorted by most relevant.
Erich Tauber, H. Kollaritsch, M. Korinek, et al.
Lancet, 2007
V. Horton, C. J. Hanthorn, A. L. Dixon, et al.
Frontiers in Sustainable Food Systems, 2024
Carmela Protano, Federica Valeriani, Katia Vitale, et al.
Vaccines, 2024
Siva N, Samantaray KK, Tripathy P, et al.
2026
Sun J, Jin X, Li H, et al.
2026
Zhengyuan Liu, Sean Hennessy, Brian L. Strom, et al.
The Journal of infectious diseases, 1997
Erich Tauber, H. Kollaritsch, F. Sonnenburg, et al.
The Journal of infectious diseases, 2008
McGuinness SL, Eades O, Morris J, et al.
2026
- Encephalitis, Japanese
- Japanese Encephalitis Vaccines
- Vaccination
ImportanceJapanese encephalitis (JE) is a mosquito-borne disease with low infection risk but high consequences. Low uptake of JE vaccines among travelers persists despite effective vaccines. Tools that improve decision quality may help address this gap.ObjectiveTo evaluate whether a web-based JE vaccine decision aid (JEVaDA) improves decision-making and vaccine uptake among Australian travelers compared with an online government JE resource.Design, setting, and participantsThis parallel-group, single-blind randomized clinical trial was conducted online across Australia from November 6, 2024, to July 14, 2025. Adults (aged ≥18 years) planning travel to a JE-endemic country within 6 months were recruited via a research panel.InterventionsParticipants were randomized 1:1 to the JEVaDA intervention, developed to International Patient Decision Aid Standards, or an online government JE resource (the active comparator).Main outcomes and measuresThe primary outcome was postintervention decisional conflict, measured using the Decisional Conflict Scale (DCS) (scores range from 0 to 100, with higher scores indicating greater conflict). Secondary outcomes included change in JE knowledge, intention to vaccinate, and self-reported vaccine uptake. Analyses used regression models adjusted for baseline values, age, and gender.ResultsOf the 1879 individuals screened, 814 were randomized and 769 completed preintervention and postintervention assessments (modified intention-to-treat population: 373 in the intervention group and 396 in the comparator group). Their mean (SD) age was 44.7 (15.2) years; 394 (51.2%) identified as women. The intervention and comparator groups showed significant reductions in decisional conflict (mean DCS score change, -10.94 [95% CI, -12.81 to -9.07] vs -11.58 [-13.24 to -9.91] points, respectively; both P Conclusions and relevanceIn this randomized clinical trial, the web-based JEVaDA was not associated with a further reduction in decisional conflict compared with an active comparator but was associated with higher vaccine uptake. These findings suggest that decision aids can support informed, values-congruent choices in complex, preference-sensitive health decisions such as travel vaccination and beyond.Trial registrationanzctr.org.au Identifier: ACTRN12624001176550.
Abstract licence: CC BY
Hiroaki Iwata, Kosuke Kakita, K. Imafuku, et al.
The Lancet. Microbe, 2021
- Encephalitis, Japanese
- Japanese Encephalitis Vaccines
- COVID-19
K. Chokephaibulkit, C. Sirivichayakul, U. Thisyakorn, et al.
The Pediatric Infectious Disease Journal, 2010
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
Not available
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 287 interactions
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
Matched from: Japanese encephalitis vaccine
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
Molecular structure

Linked open data from Wikidata (Q4007171), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. Molecular structure images from Wikimedia Commons.